Vical receives $12m production order
San-Diego-based Vical Incorporated has received around $12.1m in production orders for multiple clinical lots of DNA vaccines against HIV for the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, under a subcontract managed by SAIC-Frederick, Inc.
San-Diego-based Vical Incorporated has received around $12.1m in production orders for multiple clinical lots of DNA vaccines against HIV for the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, under a subcontract managed by SAIC-Frederick, Inc.
Production is scheduled to begin in the second half of 2005, with shipments anticipated in 2005 and 2006 in support of planned Phase II studies. The company has produced multiple DNA vaccines for the VRC against infectious disease targets including Ebola, severe acute respiratory syndrome (SARS), and West Nile virus.
'We are pleased to provide manufacturing support for the VRC's DNA vaccine development programs,' said Vijay Samant, Vical's president and chief executive officer, 'and we are particularly encouraged with their plans to advance to Phase II studies of their six-plasmid, multi-antigen, multi-clade HIV DNA vaccine.' The production orders are expected to impact revenues beginning in the second half of 2005 and the company continues to forecast a full-year net loss of $23m to $26m for 2005.